+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Anti-Tumor Drugs Market Research Report by Indications, Route of Administration, Drug, Drug Class, End User, Distribution Channels, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • ID: 5367839
  • Report
  • April 2022
  • Region: Global
  • 219 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022

FEATURED COMPANIES

  • Amgen Inc.
  • AstraZeneca plc
  • Biogen Inc.
  • Celgene Corporation
  • Eli Lilly and Company
  • Johnson & Johnson
The Global Anti-Tumor Drugs Market size was estimated at USD 27.80 billion in 2021, USD 31.13 billion in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 12.14% to reach USD 55.30 billion by 2027.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Anti-Tumor Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Indications, the market was studied across Breast Cancer, Leukemia, Lung Cancer, Melanoma, and Prostate Cancer.
  • Based on Route of Administration, the market was studied across Intra-muscular, Intraperitoneal, Intravenous, Intraventricular / Intrathecal, Intravesicular, Oral, Subcutaneous, and Topical.
  • Based on Drug, the market was studied across Alkylating Agents, Antimetabolites, Antitumor Antibiotic., Mitotic Inhibitors, and Topoisomerase Inhibitors.
  • Based on Drug Class, the market was studied across . Hormonal Therapy, Cytotoxics, and Targeted Therapy. The Targeted Therapy is further studied across Monoclonal Antibodies and Small Molecule Inhibitors.
  • Based on End User, the market was studied across Clinics, Hospitals, and Specialty Centers.
  • Based on Distribution Channels, the market was studied across Hospital Pharmacies and Retail Pharmacies.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.

This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Anti-Tumor Drugs market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Anti-Tumor Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Anti-Tumor Drugs Market, including Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Biogen Inc., Bristol-Myers Squibb, Celgene Corporation, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Anti-Tumor Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Anti-Tumor Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Anti-Tumor Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Anti-Tumor Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Anti-Tumor Drugs Market?
6. What is the market share of the leading vendors in the Global Anti-Tumor Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Anti-Tumor Drugs Market?
Frequently Asked Questions about the Global Anti-Tumor Drugs Market

What is the estimated value of the Global Anti-Tumor Drugs Market?

The Global Anti-Tumor Drugs Market was estimated to be valued at $27.8 Billion in 2021.

What is the growth rate of the Global Anti-Tumor Drugs Market?

The growth rate of the Global Anti-Tumor Drugs Market is 12.1%, with an estimated value of $55.3 Billion by 2027.

What is the forecasted size of the Global Anti-Tumor Drugs Market?

The Global Anti-Tumor Drugs Market is estimated to be worth $55.3 Billion by 2027.

Who are the key companies in the Global Anti-Tumor Drugs Market?

Key companies in the Global Anti-Tumor Drugs Market include Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Biogen Inc., Bristol, Myers Squibb, Celgene Corporation and Eli Lilly and Company.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen Inc.
  • AstraZeneca plc
  • Biogen Inc.
  • Celgene Corporation
  • Eli Lilly and Company
  • Johnson & Johnson

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in incidence of cancer across the globe with the surge in the geriatric population
5.1.1.2. Growing awareness regarding early diagnosis and treatment for the cancer
5.1.1.3. Increase in expenditures on healthcare by government
5.1.2. Restraints
5.1.2.1. Unfavorable outcomes associated with the use of cancer drugs
5.1.3. Opportunities
5.1.3.1. Rise in the number of pipelined drugs and upsurge in demand for personalized medicines for the tumor treatment
5.1.3.2. Emerging market growth potential in developing nations such as Asian and African economies
5.1.4. Challenges
5.1.4.1. High cost of anti-cancer drugs and low survival rate
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of 2022 Russia Ukraine Conflict
6. Anti-Tumor Drugs Market, by Indications
6.1. Introduction
6.2. Breast Cancer
6.3. Leukemia
6.4. Lung Cancer
6.5. Melanoma
6.6. Prostate Cancer
7. Anti-Tumor Drugs Market, by Route of Administration
7.1. Introduction
7.2. Intra-muscular
7.3. Intraperitoneal
7.4. Intravenous
7.5. Intraventricular / Intrathecal
7.6. Intravesicular
7.7. Oral
7.8. Subcutaneous
7.9. Topical
8. Anti-Tumor Drugs Market, by Drug
8.1. Introduction
8.2. Alkylating Agents
8.3. Antimetabolites
8.4. Antitumor Antibiotic.
8.5. Mitotic Inhibitors
8.6. Topoisomerase Inhibitors
9. Anti-Tumor Drugs Market, by Drug Class
9.1. Introduction
9.2. . Hormonal Therapy
9.3. Cytotoxics
9.4. Targeted Therapy
9.4.1. Monoclonal Antibodies
9.4.2. Small Molecule Inhibitors
10. Anti-Tumor Drugs Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Hospitals
10.4. Specialty Centers
11. Anti-Tumor Drugs Market, by Distribution Channels
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Retail Pharmacies
12. Americas Anti-Tumor Drugs Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Anti-Tumor Drugs Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
14. Europe, Middle East & Africa Anti-Tumor Drugs Market
14.1. Introduction
14.2. France
14.3. Germany
14.4. Italy
14.5. Netherlands
14.6. Qatar
14.7. Russia
14.8. Saudi Arabia
14.9. South Africa
14.10. Spain
14.11. United Arab Emirates
14.12. United Kingdom
15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis
15.3. Market Share Analysis, By Key Player
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration, & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding
15.4.5. Award, Recognition, & Expansion
16. Company Usability Profiles
16.1. Amgen Inc.
16.2. Astellas Pharma Inc.
16.3. AstraZeneca plc
16.4. Bayer AG
16.5. Biogen Inc.
16.6. Bristol-Myers Squibb
16.7. Celgene Corporation
16.8. Eisai Co., Ltd.
16.9. Eli Lilly and Company
16.10. F. Hoffmann-La Roche AG
16.11. Johnson & Johnson
16.12. Merck & Co., Inc.
16.13. Novartis International AG
16.14. Otsuka Pharmaceutical Co., Ltd.
16.15. Pfizer Inc.
16.16. Sanofi S.A.
16.17. Takeda Pharmaceutical Company Limited
16.18. Teva Pharmaceutical Industries Ltd.
17. Appendix
17.1. Discussion Guide
17.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL ANTI-TUMOR DRUGS MARKET: DYNAMICS
FIGURE 2. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2021 VS 2027 (%)
FIGURE 3. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2021 VS 2027 (USD BILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2027
FIGURE 5. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY BREAST CANCER, 2019-2027 (USD BILLION)
FIGURE 6. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 7. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY LEUKEMIA, 2019-2027 (USD BILLION)
FIGURE 8. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 9. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY LUNG CANCER, 2019-2027 (USD BILLION)
FIGURE 10. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 11. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MELANOMA, 2019-2027 (USD BILLION)
FIGURE 12. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 13. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PROSTATE CANCER, 2019-2027 (USD BILLION)
FIGURE 14. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 15. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2021 VS 2027 (%)
FIGURE 16. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2021 VS 2027 (USD BILLION)
FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2027
FIGURE 18. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRA-MUSCULAR, 2019-2027 (USD BILLION)
FIGURE 19. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRA-MUSCULAR, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 20. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAPERITONEAL, 2019-2027 (USD BILLION)
FIGURE 21. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 22. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENOUS, 2019-2027 (USD BILLION)
FIGURE 23. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 24. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENTRICULAR / INTRATHECAL, 2019-2027 (USD BILLION)
FIGURE 25. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENTRICULAR / INTRATHECAL, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 26. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVESICULAR, 2019-2027 (USD BILLION)
FIGURE 27. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVESICULAR, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 28. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ORAL, 2019-2027 (USD BILLION)
FIGURE 29. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 30. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SUBCUTANEOUS, 2019-2027 (USD BILLION)
FIGURE 31. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 32. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY TOPICAL, 2019-2027 (USD BILLION)
FIGURE 33. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 34. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG, 2021 VS 2027 (%)
FIGURE 35. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG, 2021 VS 2027 (USD BILLION)
FIGURE 36. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG, 2027
FIGURE 37. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ALKYLATING AGENTS, 2019-2027 (USD BILLION)
FIGURE 38. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 39. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ANTIMETABOLITES, 2019-2027 (USD BILLION)
FIGURE 40. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 41. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ANTITUMOR ANTIBIOTIC., 2019-2027 (USD BILLION)
FIGURE 42. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ANTITUMOR ANTIBIOTIC., BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 43. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MITOTIC INHIBITORS, 2019-2027 (USD BILLION)
FIGURE 44. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MITOTIC INHIBITORS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 45. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2019-2027 (USD BILLION)
FIGURE 46. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 47. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (%)
FIGURE 48. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (USD BILLION)
FIGURE 49. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2027
FIGURE 50. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY . HORMONAL THERAPY, 2019-2027 (USD BILLION)
FIGURE 51. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY . HORMONAL THERAPY, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 52. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY CYTOTOXICS, 2019-2027 (USD BILLION)
FIGURE 53. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY CYTOTOXICS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 54. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2019-2027 (USD BILLION)
FIGURE 55. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 56. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2019-2027 (USD BILLION)
FIGURE 57. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 58. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2019-2027 (USD BILLION)
FIGURE 59. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 60. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2021 VS 2027 (%)
FIGURE 61. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2021 VS 2027 (USD BILLION)
FIGURE 62. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2027
FIGURE 63. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY CLINICS, 2019-2027 (USD BILLION)
FIGURE 64. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 65. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2019-2027 (USD BILLION)
FIGURE 66. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 67. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SPECIALTY CENTERS, 2019-2027 (USD BILLION)
FIGURE 68. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 69. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2021 VS 2027 (%)
FIGURE 70. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2021 VS 2027 (USD BILLION)
FIGURE 71. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2027
FIGURE 72. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2019-2027 (USD BILLION)
FIGURE 73. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 74. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2019-2027 (USD BILLION)
FIGURE 75. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 76. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 77. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 78. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 79. CANADA ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 80. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 81. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 82. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 83. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 84. CHINA ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 85. INDIA ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 86. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 87. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 88. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 89. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 90. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 91. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 92. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 93. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 94. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 95. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 96. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 97. ITALY ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 98. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 99. QATAR ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 100. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 101. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 102. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 103. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 104. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 105. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 106. GLOBAL ANTI-TUMOR DRUGS MARKET: FPNV POSITIONING MATRIX
FIGURE 107. GLOBAL ANTI-TUMOR DRUGS MARKET: SHARE, BY KEY PLAYER, 2021
FIGURE 108. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ANTI-TUMOR DRUGS MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL ANTI-TUMOR DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2019-2027 (USD BILLION)
TABLE 4. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2019-2027 (USD BILLION)
TABLE 5. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 6. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY BREAST CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 7. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 8. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 9. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2019-2027 (USD BILLION)
TABLE 10. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 11. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY LEUKEMIA, BY STATE, 2019-2027 (USD BILLION)
TABLE 12. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 13. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 14. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2019-2027 (USD BILLION)
TABLE 15. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 16. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY LUNG CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 17. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 18. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 19. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2019-2027 (USD BILLION)
TABLE 20. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 21. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY MELANOMA, BY STATE, 2019-2027 (USD BILLION)
TABLE 22. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 23. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 24. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2019-2027 (USD BILLION)
TABLE 25. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 26. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 27. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 28. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 29. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD BILLION)
TABLE 30. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRA-MUSCULAR, BY REGION, 2019-2027 (USD BILLION)
TABLE 31. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY INTRA-MUSCULAR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 32. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY INTRA-MUSCULAR, BY STATE, 2019-2027 (USD BILLION)
TABLE 33. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY INTRA-MUSCULAR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 34. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY INTRA-MUSCULAR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 35. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2019-2027 (USD BILLION)
TABLE 36. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 37. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY STATE, 2019-2027 (USD BILLION)
TABLE 38. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 39. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 40. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2019-2027 (USD BILLION)
TABLE 41. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 42. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENOUS, BY STATE, 2019-2027 (USD BILLION)
TABLE 43. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 44. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 45. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENTRICULAR / INTRATHECAL, BY REGION, 2019-2027 (USD BILLION)
TABLE 46. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENTRICULAR / INTRATHECAL, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 47. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENTRICULAR / INTRATHECAL, BY STATE, 2019-2027 (USD BILLION)
TABLE 48. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENTRICULAR / INTRATHECAL, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 49. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENTRICULAR / INTRATHECAL, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 50. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVESICULAR, BY REGION, 2019-2027 (USD BILLION)
TABLE 51. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVESICULAR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 52. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVESICULAR, BY STATE, 2019-2027 (USD BILLION)
TABLE 53. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVESICULAR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 54. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVESICULAR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 55. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2019-2027 (USD BILLION)
TABLE 56. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 57. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY ORAL, BY STATE, 2019-2027 (USD BILLION)
TABLE 58. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 59. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 60. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2019-2027 (USD BILLION)
TABLE 61. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 62. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY STATE, 2019-2027 (USD BILLION)
TABLE 63. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 64. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 65. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2019-2027 (USD BILLION)
TABLE 66. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 67. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY TOPICAL, BY STATE, 2019-2027 (USD BILLION)
TABLE 68. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 69. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 70. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG, 2019-2027 (USD BILLION)
TABLE 71. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2019-2027 (USD BILLION)
TABLE 72. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 73. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY STATE, 2019-2027 (USD BILLION)
TABLE 74. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 76. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2019-2027 (USD BILLION)
TABLE 77. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 78. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY STATE, 2019-2027 (USD BILLION)
TABLE 79. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 81. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ANTITUMOR ANTIBIOTIC., BY REGION, 2019-2027 (USD BILLION)
TABLE 82. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY ANTITUMOR ANTIBIOTIC., BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 83. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY ANTITUMOR ANTIBIOTIC., BY STATE, 2019-2027 (USD BILLION)
TABLE 84. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY ANTITUMOR ANTIBIOTIC., BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY ANTITUMOR ANTIBIOTIC., BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 86. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MITOTIC INHIBITORS, BY REGION, 2019-2027 (USD BILLION)
TABLE 87. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY MITOTIC INHIBITORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 88. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY MITOTIC INHIBITORS, BY STATE, 2019-2027 (USD BILLION)
TABLE 89. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY MITOTIC INHIBITORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY MITOTIC INHIBITORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 91. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2019-2027 (USD BILLION)
TABLE 92. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 93. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY STATE, 2019-2027 (USD BILLION)
TABLE 94. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 96. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD BILLION)
TABLE 97. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY . HORMONAL THERAPY, BY REGION, 2019-2027 (USD BILLION)
TABLE 98. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY . HORMONAL THERAPY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 99. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY . HORMONAL THERAPY, BY STATE, 2019-2027 (USD BILLION)
TABLE 100. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY . HORMONAL THERAPY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY . HORMONAL THERAPY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 102. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY CYTOTOXICS, BY REGION, 2019-2027 (USD BILLION)
TABLE 103. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY CYTOTOXICS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 104. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY CYTOTOXICS, BY STATE, 2019-2027 (USD BILLION)
TABLE 105. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY CYTOTOXICS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY CYTOTOXICS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 107. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2019-2027 (USD BILLION)
TABLE 108. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 109. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, BY STATE, 2019-2027 (USD BILLION)
TABLE 110. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 112. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2019-2027 (USD BILLION)
TABLE 113. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 114. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY STATE, 2019-2027 (USD BILLION)
TABLE 115. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 117. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2019-2027 (USD BILLION)
TABLE 118. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 119. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY STATE, 2019-2027 (USD BILLION)
TABLE 120. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 122. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 123. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2019-2027 (USD BILLION)
TABLE 124. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 125. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY CLINICS, BY STATE, 2019-2027 (USD BILLION)
TABLE 126. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 128. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2019-2027 (USD BILLION)
TABLE 129. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 130. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, BY STATE, 2019-2027 (USD BILLION)
TABLE 131. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 133. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2019-2027 (USD BILLION)
TABLE 134. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 135. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY STATE, 2019-2027 (USD BILLION)
TABLE 136. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 138. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2019-2027 (USD BILLION)
TABLE 139. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2019-2027 (USD BILLION)
TABLE 140. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 141. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY STATE, 2019-2027 (USD BILLION)
TABLE 142. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 144. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2019-2027 (USD BILLION)
TABLE 145. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 146. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY STATE, 2019-2027 (USD BILLION)
TABLE 147. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 149. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 150. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 151. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 152. CANADA ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 153. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 154. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 155. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 156. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 157. CHINA ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 158. INDIA ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 159. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 160. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 161. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 162. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 163. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 164. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 165. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 166. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 168. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 169. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 170. ITALY ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 171. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 172. QATAR ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 173. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 174. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 175. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 176. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 177. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 178. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 179. GLOBAL ANTI-TUMOR DRUGS MARKET: SCORES
TABLE 180. GLOBAL ANTI-TUMOR DRUGS MARKET: BUSINESS STRATEGY
TABLE 181. GLOBAL ANTI-TUMOR DRUGS MARKET: PRODUCT SATISFACTION
TABLE 182. GLOBAL ANTI-TUMOR DRUGS MARKET: RANKING
TABLE 183. GLOBAL ANTI-TUMOR DRUGS MARKET: SHARE, BY KEY PLAYER, 2021
TABLE 184. GLOBAL ANTI-TUMOR DRUGS MARKET: MERGER & ACQUISITION
TABLE 185. GLOBAL ANTI-TUMOR DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 186. GLOBAL ANTI-TUMOR DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 187. GLOBAL ANTI-TUMOR DRUGS MARKET: INVESTMENT & FUNDING
TABLE 188. GLOBAL ANTI-TUMOR DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 189. GLOBAL ANTI-TUMOR DRUGS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown

Loading
LOADING...